Eagle Health Investments LP Reduces Stake in Natera, Inc. (NASDAQ:NTRA)

Eagle Health Investments LP lessened its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 21.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 339,764 shares of the medical research company’s stock after selling 91,550 shares during the period. Natera comprises 13.2% of Eagle Health Investments LP’s investment portfolio, making the stock its largest holding. Eagle Health Investments LP’s holdings in Natera were worth $53,785,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its stake in shares of Natera by 43.7% in the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company’s stock worth $1,060,836,000 after acquiring an additional 2,036,396 shares during the last quarter. Wellington Management Group LLP grew its stake in Natera by 205.4% in the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after buying an additional 1,883,481 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Natera during the 4th quarter valued at approximately $146,419,000. Vanguard Group Inc. boosted its holdings in Natera by 7.7% in the 4th quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company’s stock valued at $1,949,697,000 after purchasing an additional 879,463 shares during the period. Finally, PointState Capital LP grew its holdings in shares of Natera by 112.0% during the 3rd quarter. PointState Capital LP now owns 782,538 shares of the medical research company’s stock worth $99,343,000 after purchasing an additional 413,468 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Down 3.1 %

NTRA opened at $149.84 on Thursday. The stock’s fifty day simple moving average is $160.29 and its 200 day simple moving average is $150.55. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock has a market cap of $20.26 billion, a PE ratio of -85.14 and a beta of 1.80. Natera, Inc. has a 1-year low of $83.13 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. As a group, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Activity

In related news, insider Solomon Moshkevich sold 6,000 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $143.29, for a total value of $859,740.00. Following the sale, the insider now owns 143,768 shares of the company’s stock, valued at $20,600,516.72. The trade was a 4.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 78,553 shares of the stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the sale, the chief executive officer now owns 267,629 shares of the company’s stock, valued at approximately $44,150,756.13. This trade represents a 22.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 306,797 shares of company stock worth $48,940,883. 7.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on NTRA shares. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a research note on Wednesday, March 19th. Robert W. Baird lifted their price target on shares of Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. JPMorgan Chase & Co. boosted their target price on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Canaccord Genuity Group restated a “buy” rating and set a $180.00 target price on shares of Natera in a report on Wednesday, February 26th. Finally, BTIG Research restated a “buy” rating on shares of Natera in a report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.